A look at the millions of tax filers who chose the penalty over insurance coverage; the cost of unnecessary or excessively expensive medical care; Takeda begins the first Zika vaccine trial.
In 2015, about 6.7 million tax filers chose to pay the Affordable Care Act's penalty rather than purchase health insurance. An analysis from The New York Times took a look at who these people are and noted that while a tax filer may be an individual or a whole family, the final number is still a fraction of the 29 million Americans who were uninsured. However, more than 12 million tax filers claimed an exemption for 2015 so they didn’t have to pay the penalty for not having insurance. The number of people who paid the penalty in 2015 was down from 8.1 million in 2014.
Unnecessary or excessively expensive medical care costs the US healthcare system more than $200 billion annually. A report from ProPublica delved into waste in the healthcare system, including new supplies being thrown away and arbitrary drug expiration dates. However, it is not easy to stop the wasteful use of procedures and care. Research has also found that unnecessary care happens in the intensive care unit, which is not only expensive, but can be harmful.
The first clinical trial in the development of a vaccine for the Zika virus has started. The US government is backing the clinical trial program by Takeda. Earlier in the year, the government reduced support for development of a vaccine by Sanofi, reported Reuters. Both companies had been working on similar vaccines. Takeda expects results next year from the 240-patient phase I trial. Given the current development timeline, a vaccine likely won’t be ready until after 2020.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More